Table 3 The univariate and multivariate analyses of each recurrence pattern
From: The patterns and timing of recurrence after curative resection for gastric cancer in China
Local-regional recurrence | Distant metastasis | Peritoneum implanting | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical features | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||
OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | OR (95% CI) | p value | |
Age | ||||||||||||
≦65 | ||||||||||||
>65 | 1.173 (0.908–1.516) | 0.223 | 0.744 (0.537–1.030) | 0.075 | 1.286 (1.008–1.641) | 0.043 | 1.449 (1.093–1.922) | 0.010 | 0.552 (0.370–0.822) | 0.003 | 0.619 (0.403–0.984) | 0.029 |
Sex | ||||||||||||
Male | ||||||||||||
Female | 0.666 (0.502–0.882) | 0.005 | NA | NA | 0.825 (0.639–1.065) | 0.140 | NA | NA | 1.861 (1.330–2.603) | <0.001 | 1.687 (1.164–2.444) | 0.006 |
Hospital | ||||||||||||
Specialist hospitals | ||||||||||||
General hospitals | 1.964 (1.545–2.497) | <0.001 | 1.724 (1.312–2.265) | <0.001 | 1.664 (1.332–2.079) | <0.001 | 1.496 (1.164–1.940) | 0.002 | 1.256 (0.910–1.733) | 0.165 | NA | NA |
Tumor location | ||||||||||||
Non-GEJ | ||||||||||||
GEJ | 1.780 (1.398–2.266) | <0.001 | 1.637 (1.236–2.165) | 0.001 | 1.226 (0.973–1.546) | 0.084 | NA | NA | 0.619 (0.431–0.890) | 0.010 | 0.649 (0.437–0.965) | 0.033 |
AJCC stage | ||||||||||||
I–II | ||||||||||||
III | 1.455 (1.145–1.850) | 0.002 | NA | NA | 2.364 (1.879–2.974) | <0.001 | NA | NA | 1.627 (1.165–2.272) | 0.004 | NA | NA |
T stage | ||||||||||||
T1–2 | ||||||||||||
T3–4 | 1.752 (1.297–2.368) | <0.001 | 1.495 (1.058–2.113) | 0.023 | 2.230 (1.684–2.953) | <0.001 | 1.674 (1.210–2.316) | 0.002 | 3.291 (1.934–5.599) | <0.001 | 3.427 (1.956–6.003) | <0.001 |
N stage | ||||||||||||
N0 | ||||||||||||
N1–3 | 1.913 (1.430–2.558) | <0.001 | NA | NA | 3.179 (2.400–4.212) | <0.001 | 2.354 (1.659–3.341) | <0.001 | 1.808 (1.195–2.736) | 0.005 | NA | NA |
Positive LN ratio | ||||||||||||
≦0.33 | ||||||||||||
>0.33 | 2.287 (1.799–2.909) | <0.001 | 1.953 (1.493–2.551) | <0.001 | 2.512 (1.998–3.181) | <0.001 | 1.582 (1.214–2.128) | 0.001 | 1.509 (1.097–2.078) | 0.012 | NA | NA |
No. of LN dissection | ||||||||||||
<15 | ||||||||||||
≧15 | 0.422 (0.332–0.537) | <0.001 | NA | NA | 0.629 (0.502–0.787) | <0.001 | NA | NA | 1.094 (0.794–1.507) | 0.583 | NA | NA |
Histological type | ||||||||||||
Well-differentiated tumors | ||||||||||||
Poorly differentiated tumors | 0.881 (0.666–1.166) | 0.376 | NA | NA | 0.811 (0.623–1.057) | 0.121 | NA | NA | 1.589 (1.022–2.472) | 0.040 | 1.431 (0.889–2.303) | 0.140 |
Signet ring cell cancer | 1.308 (0.867–1.823) | 0.201 | NA | NA | 0.961 (0.645–1.433) | 0.846 | NA | NA | 3.576 (2.074–6.165) | <0.001 | 2.627 (1.449–4.761) | 0.001 |
Lymphadenectomy extent | ||||||||||||
D2 | ||||||||||||
D0/D1 | 2.442 (1.912–3.119) | <0.001 | 2.272 (1.734–2.977) | <0.001 | 1.595 (1.274–1.996) | <0.001 | 1.777 (1.369–2.307) | <0.001 | 0.933 (0.677–1.286) | 0.673 | NA | NA |
Neo-adjuvant chemotherapy | ||||||||||||
Yes | ||||||||||||
No | 1.285 (0.727–2.272) | 0.338 | NA | NA | 1.052 (0.630–1.755) | 0.847 | NA | NA | 1.560 (0.662–3.675) | 0.309 | NA | NA |
Adjuvant chemotherapy | ||||||||||||
No | ||||||||||||
Yes | 0.829 (0.598–1.149) | 0.261 | NA | NA | 0.909 (0.665–1.242) | 0.550 | NA | NA | 1.448 (0.883–2.376) | 0.142 | NA | NA |
Adjuvant chemotherapy regimen | ||||||||||||
No | ||||||||||||
Fluorouracil-based regimens | 0.801 (0.577–1.112) | 0.185 | NA | NA | 0.883 (0.645–1.208) | 0.436 | NA | NA | 1.417 (0.862–2.329) | 0.169 | NA | NA |
Other regimens | 1.649 (0.850–3.199) | 0.139 | NA | NA | 1.677 (0.862–3.263) | 0.128 | NA | NA | 1.867 (0.762–4.570) | 0.172 | NA | NA |
Adjuvant chemotherapy cycles | ||||||||||||
No | ||||||||||||
≦3 cycles | 0.754 (0.519–1.095) | 0.138 | NA | NA | 0.707 (0.495–1.008) | 0.056 | 0.640 (0.433–0.943) | 0.024 | 1.222 (0.701–2.130) | 0.479 | NA | NA |
>3 cycles | 0.880 (0.626–1.237) | 0.463 | NA | NA | 1.055 (0.762–1.461) | 0.875 | 0.842 (0.588–1.206) | 0.348 | 1.590 (0.956–2.646) | 0.074 | NA | NA |
Adjuvant radiotherapy | ||||||||||||
Yes | ||||||||||||
No | 2.609 (0.893–7.623) | 0.080 | 3.316 (0.928–11.848) | 0.065 | 2.184 (0.911–5.233) | 0.080 | 3.846 (1.226–12.068) | 0.021 | 1.229 (0.365–4.138) | 0.740 | NA | NA |